Elbasvir is an antiviral and NS5A inhibitor used to treat hepatitis C infections. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed · 2 references
Elbasvir is an inhibitor of the HCV non-structural protein 5A. While the precise role of this protein is unknown, it is essential to viral replication and virion assembly.[synthesis] Potential modes of action of NS5A inhibitors like elbasvir include blocking signaling interactions, redistribution of NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modification of the HCV replication complex.
Computational target-based in silico research suggests that elbasvir may carry activity at several proteins required for replication of SARS-CoV-2 - namely RNA-dependent RNA polymerase, helicase, and papain-like proteinase - although specific activity has yet to be affirmed by follow-up clinical studies.
- Primary indication
- Elbasvir, when used in combination with grazoprevir as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults.Curator reviewed · 4 structured indications
- Formula / weight
- C49H55N9O7 · 882.035 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2016 · European Union, 2016
- Code names
- MK-8742
- Brand names
Resolves to
BVAZQCUMNICBAQ-PZHYSIFUSA-NSMILES[H][C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=NC=C(N1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CN=C(N3)[C@]3([H])CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Elbasvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account